Kyodo University To Provide Pharmaceutical Companies iPS Cells
This article was originally published in PharmAsia News
Effective July 7, Kyodo University will begin providing human and mouse induced pluripotent stem cells to private enterprises such as pharmaceutical companies. For a fee, the university will provide iPS cells made from skin cells induced by three or four genes. The iPS research center at Kyoto University is also available to provide cell culture guidance to companies. The duration of service will be for one year and intellectual property issues will be dealt with between the center and the companies. It is the first time the school will provide such service to the private sector. Kyoto University provided mouse iPS cells to Riken Bioresource Center, a research facility, in March. (Click here for more - Japanese language
You may also be interested in...
Lead immuno-oncology asset NC318 targeting Siglec-15 showed encouraging early activity in patients refractory to PD-1/L1 inhibitors, but now Phase II plans are scuttled in lung and ovarian cancers.
Pataday Once Daily Relief Extra Strength is the same formulation as Novartis' Rx Pazeo. It will be the first OTC eye drop indicated for allergy itch with 24-hour efficacy, available online in September and through retailers in early 2021.
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.